| Cash and cash equivalents | 28.5M |
| Short-term investments | |
| Receivables | 40K |
| Prepaid and other current assets | 1.44M |
| Total current assets | 31.99M |
| Property and equipment, net | 278K |
| Notes receivable | |
| Other assets | |
| Total assets | 32.27M |
| Accounts payable | 956K |
| Accrued clinical and cost of other studies | 2.66M |
| Accrued compensation | 1.34M |
| Facility lease exit obligation | 0 |
| Other accrued liabilities | 1.12M |
| Total current liabilities | 6.08M |
| Deferred rent | |
| Facility lease exit obligation, non-current | |
| Other non-current liabilities | |
| Note payable, net of discount and accrued interest | |
| Total liabilities | 23.88M |
| Commitments and contingencies | 0 |
| Preferred stock, 5,000,000 shares authorized, none outstanding | 0 |
| Common stock, no par value; authorized shares: 213,527,214 at June 30, 2011 and December 31, 2010; issued and outstanding shares: 173,114,301 at June 30, 2011; 172,304,235 at December 31, 2010 | 438.87M |
| Accumulated deficit | -430.48M |
| Total shareholders' equity | 8.39M |
| Total liabilities and shareholders' equity | 32.27M |